High Rates of Myasthenia Gravis Exacerbations in Individuals With Pre-existing Myasthenia Gravis Exposed to Immune Checkpoint Inhibitors (P11-9.021)

Alexander Gill; Jonathan Krett; Carrie Li; Lyndsey Babcock; Yoav Piura; Andrew Morrison; Thomas Pisano; Cory Dodson; Atika Paracha; Anna Kaiser; Said Alhassan; Nikhil Modak; Iwalewa Moninuola; Maxime Jean; Jordan CARRIER; Muhammed Ikbal Arvas; Wendy Stewart; Jessica Lamb; Maria Aguilera-Pena; Celeste Camargo; Vikram Bhise; Vinay Chaudhry; Jenny Linnoila; Kottil Rammohan; Flavia Nelsion; Shamik Bhattacharyya; Meabh O’Hare; Ricardo Roda; Nicole Baldwin; Patricia Coyle; Lauryn Hemminger; Alexandra Simpson; Paula Barreras; Irena Dujmovic Basuroski; Anne Douglas; Cole Harrington; George Hutton; Kristin Galetta; Gregory Day; Sarah Conway; Shuvro Roy; Sachin Gadani; Andrew Wolf; John Probasco

doi:10.1212/wnl.0000000000213267

June 9, 2026Neurology

High Rates of Myasthenia Gravis Exacerbations in Individuals With Pre-existing Myasthenia Gravis Exposed to Immune Checkpoint Inhibitors (P11-9.021)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effects of immune checkpoint inhibitors on exacerbations in individuals with myasthenia gravis.
Examined outcomes in individuals with myasthenia gravis exposed to immune checkpoint inhibitors for cancer treatment.
Analyzed exacerbation rates and their implications for patient care.
High rates of exacerbations were observed in individuals with pre-existing myasthenia gravis post-exposure to immune checkpoint inhibitors.
Findings suggest a substantial risk linked to the use of these therapies in affected individuals.

Implication

Assesses exacerbations in individuals with myasthenia gravis after immune checkpoint inhibitors, indicating significant risks.

Abstract

To determine outcomes in people with myasthenia gravis (pwMG) after exposure to immune checkpoint inhibitors (ICIs) for comorbid oncologic indications

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gill et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f0560a7 https://doi.org/10.1212/wnl.0000000000213267

View at Publisher

Ask AI

Bookmark

Share

High Rates of Myasthenia Gravis Exacerbations in Individuals With Pre-existing Myasthenia Gravis Exposed to Immune Checkpoint Inhibitors (P11-9.021)

Key Points

Implication

Abstract

Discussion

Cite This Study

High Rates of Myasthenia Gravis Exacerbations in Individuals With Pre-existing Myasthenia Gravis Exposed to Immune Checkpoint Inhibitors (P11-9.021)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology